TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12584785
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy of western medicine
Study: 1283192
Drug: Nilvadipine (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilvadipine (16 mg q.d.)
Study: 1283192
Drug: Hydrochlorothiazide/Triamterene (HCT/T)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide/Triamterene (HCT/T) (25/50 mg q.d.)
Study: 1283192
Drug: Nilvadipine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilvadipine (1 x 8 mg)
Study: 1283192
Drug: Enalapril (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (1 x 10 mg)
Study: 3574642
Drug: 1.0 M
Normalized name: Syringe Filter 1.0 Micron
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 M sodium lactate (5 ml/kg in 5% dextrose/water) over a 20‐min period
Study: 26823970
Drug: Pragmatic advice,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pragmatic advice, manual soft tissue treatment and exercises
Study: 26823970
Drug: Pragmatic advice,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pragmatic advice, manual soft tissue treatment and exercises plus manipulative therapy
Study: 19045976
Drug: Acceptance-based behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance-based behavior therapy
Study: 10652394
Drug: Propofol/fentanyl combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol/fentanyl combination
Study: 9050095
Drug: Pressurized aerosol
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pressurized aerosol of ipratropium bromide (80 mg single dose)
Study: 9050095
Drug: Aqueous pump
Normalized name: ethylcellulose aqueous dispersion type A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous pump spray of ipratropium bromide (80 mg single dose)
Study: 22268365
Drug: Irbesartan (overall
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (overall treatment)
Study: 18091016
Drug: GABA (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: GABA (3 g)
Study: 14658966
Drug: High-dose divalproex
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose divalproex sodium
Study: 9065315
Drug: New formulation
Normalized name: TRIPROLIDINE HYDROCHLORIDE 1.25 mg in 1 mL ORAL SYRUP [HISTEX PD Drops New Formulation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: New formulation of verapamil (Veramex 40)
Study: 9065315
Drug: Standard formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard formulation of verapamil
Study: 23905576
Drug: Inhaled GS-9411
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Inhaled GS-9411 (2.4, 4.8, and 9.6 mg), dosed twice daily for 14 days
Study: 23905576
Drug: Inhaled GS-9411
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Inhaled GS-9411
Study: 21926426
Drug: Venlafaxine extended
Normalized name: Desvenlafaxine Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine extended release (ER) 37.5 to 300 mg/day
Study: 18824828
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate (LDX) 30, 50, or 70 mg/d
Study: 12952496
Drug: BIA 2‐093
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIA 2‐093 (20, 50, 100, 200, 400, 600, 900, 1200 mg)
Study: 9007129
Drug: Paclitaxel 185
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 185 mg/m2 and Carboplatin 350 mg/m2
Study: 29563072
Drug: TIMBER-K (Ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIMBER-K (Ketamine + TIMBER therapy)
Study: 29563072
Drug: TIMBER-P (Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIMBER-P (Placebo + TIMBER therapy)
Study: 27295296
Drug: Manual trigger
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual trigger point compression therapy
Study: 27295296
Drug: Manual sham
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual sham therapy
Study: 24978857
Drug: MF59-adjuvanted vaccine
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted vaccine with 3.75 μg antigen
Study: 24978857
Drug: MF59-adjuvanted vaccine
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted vaccine with 7.5 μg antigen
Study: 24978857
Drug: Nonadjuvanted vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonadjuvanted vaccine with 15 μg antigen (for children 12-35 months only)
Study: 24978857
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of MF59-adjuvanted seasonal influenza vaccine
Study: 10794804
Drug: Oral granisetron
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral granisetron 1 mg twice daily
Study: 10794804
Drug: Prochlorperazine 10
Normalized name: prochlorperazine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prochlorperazine 10 mg sustained release capsule twice daily
Study: 8989127
Drug: hBNP infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: hBNP infusion (0.003, 0.01, 0.03, and 0.1 microgram/kg per minute)
Study: 8989127
Drug: hBNP infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: hBNP infusion
Study: 30249940
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with atorvastatin and amlodipine
Study: 28411114
Drug: Plasma biologically
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma biologically active adrenomedullin (bio-ADM) on day 1 (median [Q1-Q3], 110 [59-198] pg/mL)
Study: 28411114
Drug: bio-ADM trajectory
Normalized name: Bio-Kool
Approvals — FDA: no, EMA: no, PMDA: no
Description: bio-ADM trajectory during the first week of treatment
Study: 28411114
Drug: Reduction of
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduction of bio-ADM below 110 pg/mL at day 7
Study: 20029506
Drug: Quercetin 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin 1000 mg.day(‐1) for 3 weeks
Study: 11053509
Drug: Daily iron
Normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily iron supplementation (200 mg ferrous sulfate)
Study: 11053509
Drug: Twice weekly
Normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly iron supplementation (2 x 200 mg ferrous sulfate)
Study: 2979209
Drug: Cimetidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (400 mg, 6-hourly, n = 8)
Study: 2979209
Drug: Ranitidine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (50 mg, 6-hourly, n = 10)
Study: 2979209
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (placebo, n = 12)
Study: 2979209
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (gastric ulcer patients)
Study: 20139391
Drug: Dasatinib 50
Normalized name: dasatinib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib 50 mg twice-daily
Study: 20139391
Drug: Dasatinib 140
Normalized name: dasatinib 140 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib 140 mg once-daily
Study: 20139391
Drug: Dasatinib 70
Normalized name: dasatinib 70 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib 70 mg twice-daily
Study: 20139391
Drug: Dasatinib 100
Normalized name: dasatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib 100 mg once daily for 6 months without complete cytogenetic response
Study: 18084015
Drug: Fondaparinux 2.5
Normalized name: FONDAPARINUX 2.5MG/0.5ML INJ SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fondaparinux 2.5 mg once daily subcutaneously up to 8 days
Study: 18084015
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (placebo or unfractionated heparin)
Study: 18084015
Drug: Fondaparinux vs.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fondaparinux vs. UF heparin infusion for 24-48 h
Study: 16147905
Drug: Valsartan (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (160 mg/d) at bed-time
Study: 16147905
Drug: Valsartan (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (160 mg/d) upon awakening
Study: 10645371
Drug: Concurrent tasks
Normalized name: MASK
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent tasks (verbal, visual, spatial-sequential, spatial-simultaneous)
Study: 1391736
Drug: Furazolidone (FZ)
Normalized name: Furazolidone
DrugBank: Furazolidone (DB00614)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furazolidone (FZ) high dose, 2 week course
Study: 31151239
Drug: Bilateral infraorbital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral infraorbital and infratrochlear nerve block with 8 mL of 0.5% ropivacaine
Study: 28845935
Drug: L-carnitine fumarate
Normalized name: L-carnitine fumarate
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-carnitine fumarate (1 g), acetyl-L-carnitine (0.5 g) twice daily, clomiphene citrate (CC) 25 mg twice daily, antioxidant complex (vitamins A, E, C, selenium, zinc)
Study: 28845935
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) 25 mg twice daily, antioxidant complex (vitamins)
Study: 24874591
Drug: vildagliptin +
Normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: vildagliptin + metformin
Study: 15155403
Drug: RTUF supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTUF supplement
Study: 15155403
Drug: Maize/soy flour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maize/soy flour and RTUF supplement
Study: 9220214
Drug: Buspirone 30
Normalized name: busPIRone 30 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone 30 mg/d, administered twice a day (BID)
Study: 9220214
Drug: Buspirone 30
Normalized name: busPIRone 30 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone 30 mg/d, administered three times a day (TID)
Study: 8345495
Drug: Caffeine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (250 mg) after 48 hours of abstention
Study: 8345495
Drug: Caffeine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (250 mg) after 12 hours of abstention
Study: 30478716
Drug: Microdose LSD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microdose LSD (5, 10, and 20 μg)
Study: 24938502
Drug: Rivastigmine transdermal
Normalized name: Rivastigmine Transdermal System
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine transdermal patch + physical exercises
Study: 24938502
Drug: Rivastigmine transdermal
Normalized name: Rivastigmine Transdermal System
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine transdermal patch alone
Study: 22800889
Drug: Adenosine 50
Normalized name: adenosine 50 mcg/mL-NaCl 0.9% intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine 50 µg×kg(‐1)×min(‐1) (low-dose group)
Study: 22800889
Drug: Adenosine 70
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine 70 µg×kg(‐1)×min(‐1) (high-dose group)
Study: 22800889
Drug: Saline 1
Normalized name: normal saline 10 mL Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 1 ml/min (control group)
Study: 17698695
Drug: BHT‐3009 (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: BHT‐3009 (0.5 mg, 1.5 mg, and 3 mg) administered as intramuscular injections at weeks 1, 3, 5, and 9
Study: 17698695
Drug: BHT‐3009 with
Approvals — FDA: no, EMA: no, PMDA: no
Description: BHT‐3009 with 80 mg of daily oral atorvastatin calcium
Study: 12401614
Drug: Lidocaine 1%
Normalized name: LIDOCAINE 1% LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1% (2 mL)
Study: 12401614
Drug: Metoclopramide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (10 mg, 2 mL)
Study: 10363691
Drug: No induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: No induction (no antithymocyte antibodies)
Study: 7002427
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of timolol and AHCT
Study: 7002427
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Timolol + AHCT)
Study: 30410041
Drug: TELE‐IBD Weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: TELE‐IBD Weekly
Study: 28992296
Drug: Sacubitril/valsartan 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril/valsartan 100 mg (increased to 200 mg at week 4, and 400 mg at week 10 if BP >140/90 mm Hg)
Study: 28992296
Drug: Sacubitril/valsartan (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril/valsartan (various doses as above)
Study: 28992296
Drug: Olmesartan 10
Normalized name: amlodipine-olmesartan 10 mg-20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan 10 mg (increased to 20 mg at week 4, and 40 mg at week 10 if BP >140/90 mm Hg)
Study: 19426116
Drug: Combination therapies
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapies targeting different pathways of T-cell activation
Study: 17539025
Drug: High HBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: High HBV DNA levels prior to chemotherapy
Study: 15171772
Drug: Radiofrequency treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiofrequency treatment on the left side of the face
Study: 11356768
Drug: Aspirin (1,300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (1,300 mg) with water placebo (WP)
Study: 11356768
Drug: Aspirin (1,300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (1,300 mg) with 6% CHO beverage
Study: 11356768
Drug: Aspirin (1,300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (1,300 mg) with 6% CHO+G beverage
Study: 11356768
Drug: Placebo (P)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (P) with 6% CHO+G beverage
Study: 10806751
Drug: mifepristone 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: mifepristone 12.5 mg/day po for three months
Study: 8283898
Drug: Heparin-coated extracorporeal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated extracorporeal circuit (Duraflo II)
Study: 17023704
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (2 g) plus alpha-tocopherol (800 IU)
Study: 3518646
Drug: Topical hypothermia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical hypothermia with cold potassium cardioplegia (group 1)
Study: 3518646
Drug: Topical hypothermia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical hypothermia with local interruption of the coronary circulation (group 2)
Study: 31078666
Drug: Exenatide 10
Normalized name: EXENATIDE 10MCG/DOSE 2.4ML 60D PEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide 10 µg twice-daily
Study: 31078666
Drug: Titrated insulin
Normalized name: insulin, regular, human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titrated insulin glargine (iGlar)
Study: 23689954
Drug: Augmentation Compression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentation Compression Plating (ACP)
Study: 21244590
Drug: Osteopathy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathy treatment (specific dosage and duration not mentioned)
Study: 19631303
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg GLP-2
Study: 19631303
Drug: 1.6 mg
Normalized name: menthol 1.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6 mg GLP-2
Study: 19631303
Drug: 3.2 mg
Normalized name: menthol 3.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.2 mg GLP-2
Study: 14634379
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg tamsulosin daily
Study: 14634379
Drug: Oral floroglucine‐trimetossibenzene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral floroglucine‐trimetossibenzene 3 times daily
Study: 10735806
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg urapidil
Study: 10735806
Drug: 0.4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg/kg meperidine
Study: 8872649
Drug: CHO‐E (5.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO‐E (5.5% CHO‐electrolyte solution)
Study: 6134039
Drug: Ceftriaxone (twice-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (twice-daily as single-drug therapy)
Study: 3932361
Drug: Polyvalent Pseudomonas
Normalized name: Pseudomonas aeruginosa
DrugBank: Pseudomonas aeruginosa (DB19284)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyvalent Pseudomonas vaccine (three or four dose schedule)
Study: 3932361
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (two dose schedule)
Study: 20413518
Drug: Macroalbuminuria (AER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macroalbuminuria (AER >300 mg/24 h)
Study: 20413518
Drug: Microalbuminuria (AER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microalbuminuria (AER 30-300 mg/24 h)
Study: 20413518
Drug: AER <30
Approvals — FDA: no, EMA: no, PMDA: no
Description: AER <30 mg/24 h
Study: 20413518
Drug: Overall population
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall population with sustained eGFR <60 ml/min/1.73 m(2)
Study: 11003631
Drug: Interferon alfa2a
Normalized name: ribavirin/peginterferon alfa2a 200 mg (1 tablet)-180 mcg MISCELL COMBINATION PACKAGE (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa2a plus amantadine (100 mg twice a day for 48 weeks)
Study: 6146371
Drug: Brief counselling
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief counselling without anxiolytics
Study: 27093778
Drug: Experimental oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental oral gel
Study: 27093778
Drug: Commercially available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available oral rinse
Study: 27093778
Drug: Commercially available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available mouth spray
Study: 15685717
Drug: Drug A
Normalized name: Drug additive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug A
Study: 15685717
Drug: Drug B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug B
Study: 10593372
Drug: 0.125 mg
Normalized name: digoxin 0.125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125 mg ganirelix
Study: 10593372
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg ganirelix
Study: 10593372
Drug: 0.50 mg
Normalized name: EVEROLIMUS 0.50 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.50 mg ganirelix
Study: 9206242
Drug: Ganyan IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganyan IV and Western medicine
Study: 1831630
Drug: Twice-daily oral
Normalized name: Ferriprox 1000 MG Twice-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-daily oral ondansetron treatment after a single i.v. dose prechemotherapy
Study: 1831630
Drug: Three times
Normalized name: WELLBUTRIN 100 MG Oral Tablet, Three Times Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three times a day oral supplement regimen
Study: 6984358
Drug: Tolfenamic acid
Normalized name: Tolfenamic acid
DrugBank: Tolfenamic acid (DB09216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolfenamic acid (200 mg) + Caffeine (100 mg)
Study: 6984358
Drug: Tolfenamic acid
Normalized name: Tolfenamic acid
DrugBank: Tolfenamic acid (DB09216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolfenamic acid (200 mg) + Metoclopramide (10 mg)
Study: 6984358
Drug: Tolfenamic acid
Normalized name: Tolfenamic acid
DrugBank: Tolfenamic acid (DB09216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolfenamic acid (200 mg) + Pyridoxine (300 mg)
Study: 28396221
Drug: Voice therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voice therapy (12-week protocol including vocal function exercise, hard attack, and resonance voice therapy)
Study: 25468590
Drug: Epidural catheter
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural catheter insertion with 5 mL of isotonic sodium chloride solution containing epinephrine (1:200,000)
Study: 25468590
Drug: Epidural catheter
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural catheter insertion with 5 mL of isotonic sodium chloride solution (control)
Study: 21888678
Drug: Sequential mixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential mixed mode (online followed by a paper questionnaire with reminder)
Study: 9246253
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg/day for 3 months, then increased to 40 mg/day for non-responders at 6 months)
Study: 9246253
Drug: Fluoxetine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (40 mg/day for non-responders at 6 months)
Study: 8280820
Drug: Mineral oil
Normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mineral oil (2 to 8 tablespoons twice a day for two days)
Study: 8280820
Drug: Pineapple-flavoured isotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pineapple-flavoured isotonic intestinal lavage solution (20 ml/kg/h for 4 hours on two consecutive days)
Study: 3329516
Drug: Traxanox sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traxanox sodium (120 mg)
Study: 3329516
Drug: Traxanox sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traxanox sodium (360 mg)
Study: 29064283
Drug: Clinician-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinician-guided treatment (n = 96)
Study: 29064283
Drug: Self-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-guided treatment (n = 95)
Study: 20728082
Drug: E2 (1
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: E2 (1 mg) plus drospirenone (2 mg)
Study: 2151274
Drug: Zoladex, 3.6
Normalized name: Zoladex, 3.6 mg subcutaneous implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoladex, 3.6 mg depot, plus flutamide, 250 mg t.i.d.